LAWRENCE, Mass., Sept.
8, 2015 /PRNewswire/ -- In honor of the 10th
anniversary of the Food and Drug Administration's (FDA) clearance
of its revolutionary System One™, NxStage Medical,
Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis
products, is celebrating patient milestones all summer long to
promote the significant life-changing benefits made possible with
home hemodialysis (HHD) and NxStage's decade-long role in helping
patients live better lives.
NxStage was created more than ten years ago with the mission of
improving the standard of renal care for patients. Today, the
System One is the first and only portable dialysis machine that
enables patients to perform hemodialysis in their homes or while
traveling, during the day or at night while sleeping. It has been
used to perform over twelve million treatments on thousands of
patients around the world, helping change the way patients and
clinicians think about hemodialysis. To learn more about NxStage's
history of innovation, visit Our History of Innovation for a
graphic timeline highlighting the Company's milestone
clearances.
Tina Harrison, a 45 year-old
Mumford, TN resident and military wife, has struggled with kidney
disease since she was in high school. After experiencing total
renal failure, she started in-center dialysis treatment at age 25.
After more than 13 years of in-center treatment and two
unsuccessful kidney transplants, she discovered HHD with the System
One. She then got married and began moving to different military
bases around the country as a result of her husband's military
assignments, taking the System One with her wherever they went.
Now, seven years later, Tina has extensively traveled, gone
trick or treating with her children, enjoyed bike rides and
camping, attended family weddings, gone to her son's boot camp
graduation – things she says would never have been possible without
the flexibility of the System One. Tina also recently began
performing more frequent home nocturnal hemodialysis with the
System One which has given her more time during the day to live her
life. Hear Tina's journey http://go.nxstage.com/Tina.
"The NxStage System One has given me a second life," said Tina.
"I've been able to do things I never thought possible. I no longer
worry about whether or not my husband's new station is close to a
dialysis center – I have my machine with me wherever I go. It fits
into my life."
"We're inspired by the amazing things, big and small, that our
patients have been able to achieve while performing therapy with
the NxStage System One," said Joseph E.
Turk, president of NxStage. "We're continuing to innovate to
help our patients not only live longer, but also live better
lives."
Visit NxStage's Facebook
page www.facebook.com/NxStage to read more inspiring
patient stories throughout the summer. If you would like to share
your personal achievements while using the System One please email
NxStage's patient marketing team at patientstories@nxstage.com.
For more information about the System One, home hemodialysis or
home nocturnal hemodialysis, please visit www.nxstage.com.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
Additional Risks Associated with Nocturnal Home Hemodialysis
Therapy
The NxStage System One may be used at night while the patient
and care partner are sleeping. Certain risks associated with
hemodialysis treatment are increased when performing nocturnal
therapy due to the length of treatment time and because therapy is
performed while the patient and care partner are sleeping. These
risks include, but are not limited to, blood access disconnects and
blood loss during sleep, blood clotting due to slower blood flow or
increased treatment time or both, and delayed response to alarms
when waking from sleep. Ancillary anticoagulant infusion pumps and
fluid leak detection devices may be used to decrease certain risks
for home hemodialysis treatments performed at any time, but NxStage
requires the use of fluid leak detectors to identify leaks from the
vascular access, Cycler and Cartridge when performing nocturnal
therapy with the NxStage System One.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. In addition, NxStage's Nx2Me
Connected Health platform collects important NxStage System One and
patient information for flexible viewing, monitoring and
reporting that may improve patient management and simplify
alternative site care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets
innovative products for the treatment of ESRD and acute kidney
failure. For more information on NxStage and its products, please
visit the Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the
quarter June 30, 2015. NxStage is
under no obligation to (and expressly disclaims any such obligation
to) update or alter its forward-looking statements, whether as a
result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Logo - http://photos.prnewswire.com/prnh/20150624/225341
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-recognizes-patient-life-milestones-as-part-of-10th-anniversary-celebration-300134543.html
SOURCE NxStage Medical, Inc.